Cephalon buys muscle relaxant drug

Eurand, which developed Amrix for ECR, will now work with Cephalon to support the commercialization of the product in the US. Eurand will receive royalty payments from Cephalon on Amrix sales. ECR received approval of Amrix for short-term use as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions, in February from the FDA.

Gearoid Faherty, CEO of Eurand, said: “We would like to recognize the efforts of our partner, ECR, in obtaining regulatory approval for Amrix and look forward to working with Cephalon in commercialization of the product in the US.”